678 related articles for article (PubMed ID: 11590527)
21. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
van Praag RM; Weverling GJ; Portegies P; Jurriaans S; Zhou XJ; Turner-Foisy ML; Sommadossi JP; Burger DM; Lange JM; Hoetelmans RM; Prins JM
AIDS; 2000 Jun; 14(9):1187-94. PubMed ID: 10894283
[TBL] [Abstract][Full Text] [Related]
22. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
[TBL] [Abstract][Full Text] [Related]
23. Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
Wasmuth JC; Rodermann E; Voigt E; Vogel M; Lauenroth-Mai E; Jessen A; Burger D; Rockstroh JK
Eur J Med Res; 2007 Jul; 12(7):289-94. PubMed ID: 17933700
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
Acosta EP; Wu H; Hammer SM; Yu S; Kuritzkes DR; Walawander A; Eron JJ; Fichtenbaum CJ; Pettinelli C; Neath D; Ferguson E; Saah AJ; Gerber JG;
J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1358-66. PubMed ID: 15483465
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
26. A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.
Floridia M; Tomino C; Bucciardini R; Ricciardulli D; Fragola V; Pirillo MF; Amici R; Giannini G; Galluzzo CM; Andreotti M; Seeber AC; Ammassari A; Cingolani A; Lazzarin A; Scalise G; Cargnel A; Suter F; Milazzo F; Pastore G; Moroni M; Ciammarughi R; Pini R; Carosi G; D'Amato C; Contu L; Concia E; Bonazzi L; Aiuti F; Vigevani G; Vella S;
AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1809-20. PubMed ID: 11118067
[TBL] [Abstract][Full Text] [Related]
27. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
Lichterfeld M; Nischalke HD; Bergmann F; Wiesel W; Rieke A; Theisen A; Fätkenheuer G; Oette M; Carls H; Fenske S; Nadler M; Knechten H; Wasmuth JC; Rockstroh JK
HIV Med; 2002 Jan; 3(1):37-43. PubMed ID: 12059949
[TBL] [Abstract][Full Text] [Related]
29. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
[TBL] [Abstract][Full Text] [Related]
30. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
31. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
[TBL] [Abstract][Full Text] [Related]
32. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.
Smith D; Hales G; Roth N; Law M; Ray J; Druett J; Mitchell J; Mills G; Doong N; Franklin R;
HIV Clin Trials; 2001; 2(2):97-107. PubMed ID: 11590517
[TBL] [Abstract][Full Text] [Related]
33. Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure.
González de Requena D; Gallego O; de Mendoza C; Corral A; Jiménez-Nácher I; Soriano V
AIDS Res Hum Retroviruses; 2003 Jun; 19(6):457-9. PubMed ID: 12882654
[TBL] [Abstract][Full Text] [Related]
34. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
[TBL] [Abstract][Full Text] [Related]
36. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
[TBL] [Abstract][Full Text] [Related]
37. Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up.
Justesen US; Levring AM; Thomsen A; Lindberg JA; Pedersen C; Tauris P
HIV Med; 2003 Jul; 4(3):250-4. PubMed ID: 12859324
[TBL] [Abstract][Full Text] [Related]
38. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C
AIDS; 2010 Jan; 24(2):223-30. PubMed ID: 20010070
[TBL] [Abstract][Full Text] [Related]
39. [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Geijo Martínez MP; Maciá Martínez MA; Solera Santos J; Barberá Farré JR; Rodríguez Zapata M; Marcos Sánchez F; Martínez Alfaro E; Cuadra García-Tenorio F; Sanz Moreno J; Moreno Mendaña JM; Beato Pérez JL; Sanz Sanz J;
Rev Clin Esp; 2006 Feb; 206(2):67-76. PubMed ID: 16527165
[TBL] [Abstract][Full Text] [Related]
40. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
